thalidomide has been researched along with Degenerative Diseases, Central Nervous System in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The immunomodulatory imide drug (IMiD) class, which includes the founding drug member thalidomide and later generation drugs, lenalidomide and pomalidomide, has dramatically improved the clinical treatment of specific cancers, such as multiple myeloma, and it combines potent anticancer and anti-inflammatory actions." | 5.41 | A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. ( Glotfelty, EJ; Greer, ME; Greig, NH; Hsueh, SC; Kim, DS; Kopp, KO; Reale, M; Tweedie, D; Vargesson, N, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kopp, KO | 1 |
| Greer, ME | 1 |
| Glotfelty, EJ | 1 |
| Hsueh, SC | 1 |
| Tweedie, D | 1 |
| Kim, DS | 1 |
| Reale, M | 1 |
| Vargesson, N | 1 |
| Greig, NH | 2 |
| Giordano, T | 1 |
| Zhu, X | 1 |
| Yu, QS | 1 |
| Perry, TA | 1 |
| Holloway, HW | 1 |
| Brossi, A | 1 |
| Rogers, JT | 1 |
| Sambamurti, K | 1 |
| Lahiri, DK | 1 |
| Kumar, S | 1 |
| Li, C | 1 |
1 review available for thalidomide and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders.
Topics: Humans; Immunomodulating Agents; Multiple Myeloma; Neurodegenerative Diseases; Neuroinflammatory Dis | 2023 |
2 other studies available for thalidomide and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases.
Topics: Cells, Cultured; Humans; Immunosuppressive Agents; Neurodegenerative Diseases; Thalidomide; Tumor Ne | 2004 |
Targeting of vasculature in cancer and other angiogenic diseases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antigens, CD; Arthritis, Rheumatoid; Diabetic Retin | 2001 |